Price T Rowe Associates Inc Supernus Pharmaceuticals, Inc. Call Options Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding SUPN
# of Institutions
264Shares Held
59.4MCall Options Held
47.9KPut Options Held
13.1K-
Black Rock Inc. New York, NY10.4MShares$392 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.14MShares$232 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.27MShares$199 Million1.83% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$109 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.68MShares$101 Million0.08% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $2.02B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...